A 52-year-old man with a family history of premature coronary artery disease presents with xanthomas on the Achilles tendons and eyelids. Lipid panel shows total cholesterol 580 mg/dL, LDL 480 mg/dL, HDL 35 mg/dL, and triglycerides 150 mg/dL. Regarding the pathophysiology and management of his condition, all of the following are true EXCEPT:

Question

Accepted Answer

C. Ezetimibe should be avoided in this patient because it increases LDL receptor expression and will worsen the underlying genetic defect. ## Familial Hypercholesterolemia (FH): Pathophysiology and Management

**Key Point:** This patient has **Heterozygous Familial Hypercholesterolemia (HeFH)**, characterized by LDL receptor dysfunction. Option 3 is incorrect because ezetimibe is actually **beneficial** and should NOT be avoided — it is part of combination therapy.

### Clinical Features of HeFH:

- **Xanthomas**: Tendon xanthomas (especially Achilles), eyelid xanthomas (xanthelasmas)
- **Lipid profile**: Markedly elevated LDL (typically 300–600 mg/dL), normal or low triglycerides
- **Age of presentation**: Premature CAD in 3rd–4th decade in males; family history of early MI
- **Prevalence**: 1 in 250–500 individuals

### Pathophysiology (Options 0 is CORRECT):

```mermaid
flowchart TD
  A[LDL Receptor Gene Mutation]:::outcome --> B[Reduced LDL Receptor Expression]:::outcome
  B --> C[↓ Hepatic LDL Uptake]:::outcome
  C --> D[↑ Circulating LDL]:::outcome
  D --> E[Accelerated Atherosclerosis]:::urgent
  E --> F[Premature CAD, Xanthomas]:::urgent
```

### Management Strategies (Options 1 & 2 are CORRECT):

| Agent | Mechanism | Effect on LDL | Role in HeFH |
|---|---|---|---|
| **Statins** | Inhibit HMG-CoA reductase | ↓ Cholesterol synthesis; ↑ LDL receptor expression | First-line; reduces LDL by 30–50% |
| **Ezetimibe** | Inhibits NPC1L1 (cholesterol absorption) | ↓ Intestinal cholesterol uptake | Add-on therapy; reduces LDL by additional 15–20% |
| **PCSK9 inhibitors** | Block PCSK9 (LDL receptor degradation) | ↑ LDL receptor recycling; ↓ LDL by 50–70% | Second-line or add-on; highly effective |
| **Bempedoic acid** | Inhibits uric acid synthesis (upstream of cholesterol) | Modest LDL reduction | Adjunctive agent |

**High-Yield:** PCSK9 inhibitors are **game-changers** in HeFH because they prevent the degradation of LDL receptors, allowing them to recycle back to the hepatocyte surface and capture more LDL particles.

### Why Option 3 is WRONG:

**Ezetimibe is NOT contraindicated; it is RECOMMENDED as add-on therapy.**

1. **Mechanism**: Ezetimibe blocks NPC1L1 (Niemann-Pick C1-like 1) transporter in the intestinal brush border, reducing cholesterol absorption.
2. **Effect on LDL receptors**: Ezetimibe does **increase** LDL receptor expression (via feedback upregulation), but this is **beneficial**, not harmful.
3. **Synergy with statins**: Ezetimibe + statin combination reduces LDL by ~50%, compared to statin monotherapy (~30–40%).
4. **Current guidelines**: Ezetimibe is part of standard combination therapy in HeFH, especially in heterozygous patients.

**Clinical Pearl:** Homozygous FH (2 mutant alleles) presents in childhood with LDL >600 mg/dL, widespread xanthomas, and MI by age 10–20 without aggressive treatment. These patients require combination therapy (statin + ezetimibe + PCSK9 inhibitor ± apheresis).

**Warning:** Do not confuse the effect of ezetimibe on LDL receptors with worsening of the genetic defect. Increasing LDL receptor expression is exactly what we want in FH patients — it helps compensate for the underlying receptor dysfunction.

**Mnemonic:** **"SEPIA"** for HeFH management:
- **S**tatins (first-line)
- **E**zetimibe (add-on)
- **P**CSK9 inhibitors (potent add-on)
- **I**ncretins / **I**ncisive lifestyle (diet, exercise)
- **A**pheresis (severe/homozygous cases)

Answer

A. PCSK9 inhibitors are effective because they prevent degradation of LDL receptors on hepatocyte surfaces, increasing their recycling

Answer

B. The defect involves loss-of-function mutations in the LDL receptor gene, reducing hepatic uptake of LDL particles

Answer

D. Statins are the first-line pharmacological agent and work by inhibiting HMG-CoA reductase to reduce cholesterol synthesis

Explanation

Practice similar questions